Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | CHKA | P35790 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24061111 | 0.91 | MC4R (0.56) | MC4RSIGMAR1FAAHCHKAHRH3 | |
| SCHEMBL13535291 | 0.87 | MC4R (0.74) | MC4RSIGMAR1CHKAHRH3LMNA | |
| SCHEMBL13382006 | 0.86 | ALDH1A1 (0.59) | SIGMAR1FAAHHTR2ANPC1TP53 | |
| SCHEMBL2225221 | 0.84 | PRMT6 (0.62) | SIGMAR1FAAHHRH3PRMT6HTR2A | |
| SCHEMBL26149604 | 0.82 | SMN1; SMN2 (0.64) | SIGMAR1FAAHHRH3PRMT6 | |
| SCHEMBL13377361 | 0.82 | FAAH (0.50) | SIGMAR1FAAHNCF1PRMT6HTR2A | |
| SCHEMBL12830614 | 0.81 | MC4R (0.65) | MC4RSIGMAR1CHKAHRH3LMNA | |
| SCHEMBL10076573 | 0.81 | MC4R (0.65) | MC4RFAAHHRH3LMNA | |
| SCHEMBL16314612 | 0.81 | SIGMAR1 (0.54) | SIGMAR1FAAHHTR2A | |
| SCHEMBL18946202 | 0.80 | LMNA (0.62) | SIGMAR1FAAHLMNAPRMT6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2393780-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | disclosed |
| WO-2010089119-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2007058626-A1 | INDAZOLE COMPOUNDS | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GRIK5, HRH2 | MC4R 183/4885SIGMAR1 1225/4885FAAH 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.